FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2541779494> ?p ?o ?g. }

• W2541779494 endingPage "S1300" @default.
• W2541779494 startingPage "S1299" @default.
• W2541779494 abstract "For patients with advanced NSCLC without genetic driver alterations, cisplatin/carboplatin+pemetrexed is a standard-of-care first-line (1L) treatment for non-squamous histology; and cisplatin/carboplatin+gemcitabine for squamous histology. Although immunotherapies targeting PD-L1/PD-1 are currently available for 2L+ NSCLC, chemotherapy remains the main 1L option despite poor survival and toxicities. Atezolizumab, an anti–PDL1 mAb, prevents PD-L1 from interacting with its receptors PD-1 and B7.1, restoring tumor-specific T-cell immunity. Clinical efficacy was demonstrated with atezolizumab in non-squamous and squamous NSCLC, with Phase I and II studies exhibiting durable responses and survival benefit that increases with higher PD-L1 expression on tumor cells (TC) and/or tumor-infiltrating immune cells (IC). IMpower110, a global Phase III randomized, multicenter, open-label trial, will evaluate efficacy and safety of atezolizumab vs cisplatin/carboplatin+pemetrexed or gemcitabine as 1L therapy for PD-L1–selected chemotherapy-naive patients with advanced non-squamous or squamous NSCLC, respectively. Eligibility criteria include stage IV non-squamous or squamous NSCLC, measurable disease (RECIST v1.1), ECOG PS 0-1, no prior chemotherapy for advanced NSCLC and centrally-assessed PD-L1 expression ≥1% on TC or IC (TC1/2/3 or IC1/2/3 with VENTANA SP142 IHC assay; expected prevalence, ≈65%). Exclusion criteria include active or untreated CNS metastases, prior immune checkpoint blockade therapy or autoimmune disease. Patients will be randomized 1:1 to receive atezolizumab or cisplatin/carboplatin+pemetrexed (non-squamous)/gemcitabine (squamous) for 4 or 6 21-day cycles. Patients in comparator arms can receive pemetrexed (non-squamous)/best supportive care (squamous) until RECIST v1.1 disease progression. Patients receiving atezolizumab may continue until loss of clinical benefit. Co-primary endpoints are PFS and OS. Key secondary efficacy endpoints include ORR, DOR, IRF-assessed PFS (RECIST v1.1) and TTD. Safety and PK will also be evaluated. Tumor biopsies at RECIST v1.1 progression will be assessed for immunologic biomarkers associated with responses to atezolizumab and to differentiate non-conventional responses from radiographic progression.Tabled 1Planned enrollment, N570HistologyNon-squamousSquamousExperimental armAtezolizumab (1200 mg q3w)Comparator armCisplatin (75 mg/m2 IV q3w) + pemetrexed (500 mg/m2 IV q3w) or Carboplatin (AUC 6 mg/mL/min IV q3w) + pemetrexed (500 mg/m2 IV q3w)Cisplatin (75 mg/m2 IV q3w) + gemcitabine (1200 mg/m2 IV days 1, 8) or Carboplatin (AUC 5 mg/mL/min IV q3w) + gemcitabine (1000 mg/m2 IV days 1, 8)Stratification factors• Sex• ECOG• Histology (non-squamous vs squamous)• PD-L1 expression by IHCClinicalTrials.gov identifierNCT02409342 Open table in a new tab Section not applicable. Section not applicable." @default.
• W2541779494 created "2016-11-04" @default.
• W2541779494 creator A5003664573 @default.
• W2541779494 creator A5004874011 @default.
• W2541779494 creator A5008593691 @default.
• W2541779494 creator A5018054038 @default.
• W2541779494 creator A5019136919 @default.
• W2541779494 creator A5019770739 @default.
• W2541779494 creator A5054996413 @default.
• W2541779494 creator A5072962574 @default.
• W2541779494 creator A5078389632 @default.
• W2541779494 creator A5081764461 @default.
• W2541779494 date "2017-01-01" @default.
• W2541779494 modified "2023-09-30" @default.
• W2541779494 title "P3.02c-042 IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients" @default.
• W2541779494 doi "https://doi.org/10.1016/j.jtho.2016.11.1837" @default.
• W2541779494 hasPublicationYear "2017" @default.
• W2541779494 type Work @default.
• W2541779494 sameAs 2541779494 @default.
• W2541779494 citedByCount "0" @default.
• W2541779494 crossrefType "journal-article" @default.
• W2541779494 hasAuthorship W2541779494A5003664573 @default.
• W2541779494 hasAuthorship W2541779494A5004874011 @default.
• W2541779494 hasAuthorship W2541779494A5008593691 @default.
• W2541779494 hasAuthorship W2541779494A5018054038 @default.
• W2541779494 hasAuthorship W2541779494A5019136919 @default.
• W2541779494 hasAuthorship W2541779494A5019770739 @default.
• W2541779494 hasAuthorship W2541779494A5054996413 @default.
• W2541779494 hasAuthorship W2541779494A5072962574 @default.
• W2541779494 hasAuthorship W2541779494A5078389632 @default.
• W2541779494 hasAuthorship W2541779494A5081764461 @default.
• W2541779494 hasBestOaLocation W25417794941 @default.
• W2541779494 hasConcept C121608353 @default.
• W2541779494 hasConcept C126322002 @default.
• W2541779494 hasConcept C143998085 @default.
• W2541779494 hasConcept C2775949291 @default.
• W2541779494 hasConcept C2776694085 @default.
• W2541779494 hasConcept C2777240266 @default.
• W2541779494 hasConcept C2777701055 @default.
• W2541779494 hasConcept C2778239845 @default.
• W2541779494 hasConcept C2780057760 @default.
• W2541779494 hasConcept C2780258809 @default.
• W2541779494 hasConcept C2781451048 @default.
• W2541779494 hasConcept C71924100 @default.
• W2541779494 hasConceptScore W2541779494C121608353 @default.
• W2541779494 hasConceptScore W2541779494C126322002 @default.
• W2541779494 hasConceptScore W2541779494C143998085 @default.
• W2541779494 hasConceptScore W2541779494C2775949291 @default.
• W2541779494 hasConceptScore W2541779494C2776694085 @default.
• W2541779494 hasConceptScore W2541779494C2777240266 @default.
• W2541779494 hasConceptScore W2541779494C2777701055 @default.
• W2541779494 hasConceptScore W2541779494C2778239845 @default.
• W2541779494 hasConceptScore W2541779494C2780057760 @default.
• W2541779494 hasConceptScore W2541779494C2780258809 @default.
• W2541779494 hasConceptScore W2541779494C2781451048 @default.
• W2541779494 hasConceptScore W2541779494C71924100 @default.
• W2541779494 hasIssue "1" @default.
• W2541779494 hasLocation W25417794941 @default.
• W2541779494 hasOpenAccess W2541779494 @default.
• W2541779494 hasPrimaryLocation W25417794941 @default.
• W2541779494 hasRelatedWork W1967863863 @default.
• W2541779494 hasRelatedWork W2471989939 @default.
• W2541779494 hasRelatedWork W2569260518 @default.
• W2541779494 hasRelatedWork W2912044537 @default.
• W2541779494 hasRelatedWork W2914770343 @default.
• W2541779494 hasRelatedWork W2948776902 @default.
• W2541779494 hasRelatedWork W3033877262 @default.
• W2541779494 hasRelatedWork W3037140139 @default.
• W2541779494 hasRelatedWork W4283526032 @default.
• W2541779494 hasRelatedWork W4295837280 @default.
• W2541779494 hasVolume "12" @default.
• W2541779494 isParatext "false" @default.
• W2541779494 isRetracted "false" @default.
• W2541779494 magId "2541779494" @default.
• W2541779494 workType "article" @default.